home / stock / nltx / nltx news

NLTX News and Press, Neoleukin Therapeutics Inc. From 01/10/22

Stock Information
Company Name: Neoleukin Therapeutics Inc.
Stock Symbol: NLTX
Market: NYSE
Menu
NLTX NLTX Quote NLTX Short NLTX News NLTX Articles NLTX Message Board
Get NLTX Alerts

News, Short Squeeze, Breakout and More Instantly...
NLTX - Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)

- NL-201 plus pembrolizumab to be evaluated in advanced solid tumor patients - - Combination testing anticipated to begin in 2022 - SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company uti...
NLTX - Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference

SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executi...

NLTX - Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)

– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin lymphoma model – SEATTLE, Dec. 11, 2021 (GLOBE NEWS...

NLTX - Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021)

SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of new preclinical data on...
NLTX - Neoleukin Therapeutics to Present at Upcoming Investor Conferences

SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that management will participate in two upc...

NLTX - Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update

– NL-201 Phase 1 solid tumor trial interim data anticipated in 2022 – – Upcoming presentations at ACR, SITC, and ASH to highlight preclinical data – – Planning to initiate a Phase 1 trial in hematologic malignancies with NL-201 in 202...

NLTX - Tracking Baker Brothers Portfolio - Q2 2021 Update

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
NLTX - Neoleukin Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021)

SEATTLE, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the acceptance of four abstracts to be pres...

NLTX - Neoleukin Therapeutics Announces Oral Presentation at IDWeek 2021 of Data Demonstrating that NL-CVX1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Concern

– Single intranasal dose of NL-CVX1 in mice prevents infection by multiple variants of SARS-CoV-2 – – Transgenic mice that are protected from disease by NL-CVX1 remain resistant to rechallenge after one month – SEATTLE, Sept. 29, 2021 (GLOBE N...

NLTX - Neoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of Research

SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Bill Arthur, Ph.D., as ...
Previous 10 Next 10